Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Osteoporosis prevention is important in patients with osteopenia (low bone density). This
study will test the safety and efficacy of zoledronic acid in patients diagnosed with
osteopenia.